Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Mednax 3Q profit rises 27 percent

November 2, 2010 11:45 am | by The Associated Press | News | Comments

National physician group Mednax Inc. said Tuesday that its third-quarter profit rose 27 percent as contributions from newly acquired practices helped boost revenue.Mednax earned $61.3 million, or $1.29 per share, up from $48.1 million, or $1.03 per share, in the same quarter last year. Revenue...

Emergency Medical Services 3Q profit rises

November 2, 2010 11:45 am | by The Associated Press | News | Comments

GREENWOOD VILLAGE, Colo. (AP) — Ambulance services provider Emergency Medical Services Corp. said Tuesday its third-quarter net income rose 27 percent on a boost in new contracts and acquisitions.EMS reported net income of $36.8 million, or 82 cents per share, up from $28.9 million, or 66 cents per...

Genstruct names systems biology vet Levine to board

November 2, 2010 10:37 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Genstruct Inc., a systems biology firm located in Cambridge, has appointed oncology and systems biology leader Arnold Levine to the company's board of directors.

Advertisement

Ironwood inches toward NDA on positive Phase 3 results

November 2, 2010 10:37 am | by Mass High Tech: The Journal of New England Technology | News | Comments

A treatment for irritable bowel syndrome developed by Cambridge-based Ironwood Pharmaceuticals Inc. and partner Forest Laboratories Inc., of New York, has achieved positive results in a second Phase 3 clinical trial, meeting both primary and secondary endpoints.

Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant

November 2, 2010 10:36 am | by Bio-Medicine.Org | News | Comments

RYE, N.Y., Nov. 2, 2010 /- Curemark LLC , a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to...

TOPICS:

GREENGUARD's First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently

November 2, 2010 10:35 am | by Bio-Medicine.Org | News | Comments

ATLANTA, Nov. 2, 2010 /PRNewswire-USNewswire/ -- Architects and designers who visit the GREENGUARD Environmental Institute 's first-ever HEALTHCARE DESIGN.10 exhibit next week will have the opportunity to learn how low-emitting products and materials can help create healthier, more...

TOPICS:

GeNO LLC Submits Investigational New Drug Application for Its NITROsylâ„¢ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension

November 2, 2010 10:35 am | by Bio-Medicine.Org | News | Comments

COCOA, Fla., Nov. 2, 2010 /- GeNO LLC ( www.genollc.com ) a privately held, advanced development-stage technology company announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for the GeNO NITROsyl (Inhaled Nitric...

TOPICS:

RoundTable Healthcare Partners Acquires Majority Stake in Salter Labs

November 2, 2010 10:35 am | by Bio-Medicine.Org | News | Comments

LAKE FOREST, Ill., Nov. 2, 2010 /- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has acquired a majority interest in Salter Labs ("Salter").  Founded in 1976 by Peter...

TOPICS:
Advertisement

Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Su...

November 2, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, Nov. 2, 2010 /PRNewswire-USNewswire/ -- Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH)...

TOPICS:

Class I Medical Device Recall: Medtronic Octopus Nuvo Tissue Stabilizer, Model TSMICS1

November 2, 2010 10:30 am | by U.S. Food & Drug Administration | News | Comments

This device stabilizes and minimizes the motion of selected areas of the beating heart during minimally invasive cardiac procedures while directly visualizing the heart through a small cut in the chest cavity.

TOPICS:

Los Angeles-Based M & A Expert Expands Firm's Transactional Practice

November 2, 2010 9:46 am | by The Associated Press | News | Comments

Jeryl A. Bowers has joined the Los Angeles/Century City office of Sheppard, Mullin, Richter & Hampton LLP as a partner in the firm's Corporate practice group. Bowers most recently was a partner at K&L Gates in Los Angeles.Bowers concentrates his practice in mergers and acquisitions and ...

Tenet Healthcare 3Q profit surges on tax benefit(2)

November 2, 2010 9:46 am | by The Associated Press | News | Comments

Hospital operator Tenet Healthcare Corp. on Tuesday reported a profit in the third quarter on $981 million in deferred tax benefits.The company earned $932 million, or $1.68 per share, compared with a loss of $3 million, or a penny per share, during the same period a year prior. Revenue...

Tenet Healthcare 3Q profit surges on tax benefit

November 2, 2010 9:45 am | News | Comments

Hospital operator Tenet Healthcare Corp. on Tuesday reported a profit in the third quarter on $981 million in deferred tax benefits.The company earned $932 million, or $1.68 per share, compared with a loss of $3 million, or a penny per share, during the same period a year prior. Revenue...

BioScrip 3Q profit falls 66 pct; new CEO announced

November 2, 2010 8:45 am | by The Associated Press | News | Comments

BioScrip Inc.'s net income fell by two-thirds in the third quarter, the pharmacy benefits manager said Tuesday, on a surge in operating expenses following the buyout of Critical Homecare Solutions in March.Meanwhile, the company said Richard M. Smith will replace Richard H. Friedman as CEO on...

Global map of the sickle cell gene supports 'malaria hypothesis'

November 2, 2010 8:34 am | by EurekAlert | News | Comments

(Wellcome Trust) At a global scale, the sickle cell gene is most commonly found in areas with historically high levels of malaria, adding geographical support to the hypothesis that the gene, whilst potentially deadly, avoids disappearing through natural selection by providing...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading